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A B S T R A C T
The increasing application of nanomaterials and the notion that their distinct features compared to larger sized
counterparts should be considered in safety assessment, has led to the development of risk assessment frame-
works that are specific to nanomaterials. These frameworks aim to prioritise, rank or assess the safety of a
nanomaterial efficiently by targeting critical information in order to conserve resources. The present overview
shows that each nanomaterial framework has its own scope, advantages and disadvantages and all except one
lack details such as decision criteria to come to conclusions and enable actual application. Those frameworks
directed towards gaining information and making decisions on regulatory submissions at national and EU level
are principally of interest. Additionally, those aimed at informing decision-making in the innovation chain are
important.
This manuscript also discusses issues relevant for exposure and hazard assessment of nanomaterials such as
life cycle, bioaccumulation and delivered dose that should be considered in risk assessment frameworks.
Elements for improving the feasibility to perform risk assessment in practice include standardised testing,
knowledge on in vitro-in vivo comparison and functional assays. With this information and the need to increase
the efficiency in risk assessment, future perspectives are outlined. Grouping and read-across approaches can
bring some efficiency compared to a case-by-case approach. However, science is at present not advanced enough
to fully substantiate decision criteria and specific protocols needed to considerably increase the efficiency. A
possible way forward would be to pursue the development of a pragmatic and internationally accepted nano-
material decision framework with decision criteria that can only be partially scientifically based. This would
require the cooperation of policy makers, scientists and industry.
1. Introduction
Nanomaterials are increasingly used as their different features,
compared to their larger sized counterparts, can be applied in in-
novative products and materials. Such changes in functionality can be
made by modifying chemical make-up, size, shape, surface character-
istics et cetera. The physicochemical properties that provide specific
functionality, can also affect the behaviour of nanomaterials in the
environment and humans, which may result in different exposures
(including different sites in the environment or within the human body)
and subsequent hazards. It is therefore relevant to consider the poten-
tial risks of nanomaterials. This should be done in such a manner that
sufficient information becomes available to assess the risk of each na-
nomaterial and allows innovative nanotechnologies to be developed.
The basic components of risk assessment of chemicals are hazard
and exposure assessments, dose-response estimation, risk characterisa-
tion, and accounting for uncertainty in the overall assessment. While
this traditional risk assessment paradigm also holds for nanomaterials
(SCENIHR, 2005, 2007, 2009; Sayre and Steinhäuser, 2016; OECD,
2012a), many of the tools, test protocols and guidelines for determi-
nation and assessment of physicochemical properties, fate, exposures,
and effects used for conventional chemicals, need modifications when
applied to (the regulatory) evaluation of nanomaterials (Sayre and
Steinhäuser, 2016).
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In the context of this article, the term risk assessment “framework”
is used in the same context that it is used by the National Academy of
Sciences (NAS, 2009): it is intended to incorporate the traditional risk
assessment paradigm applied to chemicals (NAS, 1983) in broader
sense to allow for a flexible risk assessment approach for decision-
making. This encompasses both human health and environmental
endpoints, and incorporates concepts such as the following: default
assumptions, read-across, overarching general risk assessment para-
digms, and specific tiered-testing schemes. Recently, more risk assess-
ment frameworks and assessment methodologies, sometimes also re-
ferred to as tiered-testing approaches or schemes, strategies or
methodologies, have emerged that are specific to nanomaterials. These
frameworks aim to prioritise, rank or assess the safety of a substance/
nanomaterial efficiently by targeting critical information, i.e. aiming to
obtain the necessary information for risk assessment, while conserving
resources.
The aim of the present manuscript is to assess nanomaterial testing
and assessment frameworks that are most useful in a regulatory context.
Those frameworks, which are mainly directed towards gaining in-
formation and making decisions on regulatory submissions at national
and EU-wide levels are principally of interest. Additionally, frameworks
to inform decision-making in the innovation chain are important.
Several nanospecific issues in risk assessment and elements for im-
proving the feasibility to assess the risks of nanomaterials are ad-
dressed. The frameworks are discussed in relation to the need to in-
crease the efficiency in information gathering for risk assessment of
nanomaterials. Finally, recommendations, future perspectives and
conclusions are provided and discussed. These include process-related
considerations on how such perspectives can be achieved.
2. Methods and criteria to select and evaluating risk assessment
frameworks
As noted in Sayre et al. (2017), experts in nine different disciplines
(including those with expertise in regulatory assessments, physico-
chemical properties, fate, effects, modelling, and risk assessment) re-
viewed the relevant publications and reports of 23 research and reg-
ulatory bodies from the EU, the US, the OECD, and Germany, as well as
references from open literature. In total, approximately 1000 references
from both the peer-reviewed and grey literature were evaluated
(Steinhäuser and Sayre, 2017). All experts commented on the utility of
the risk assessment frameworks, and their components, that were
contained in these publications.
The overarching criteria used to select and evaluate the risk as-
sessment frameworks, covering human health and/or environment, are
those applied by the OECD to judge the utility of any regulatory
method, protocol, or data set: is the risk assessment framework both
relevant (to predicting endpoints of interest for regulatory purposes)
and reliable (OECD, 2005)? In addition, the risk assessment frameworks
and testing schemes were evaluated relative to how responsive they
were to a set of regulatory questions specific to nanomaterials, as
generated by regulatory programs and experts who are involved in
nanomaterial regulatory risk assessments (Sayre et al., 2017). These
questions were developed to determine which risk assessment frame-
works were most useful for use early in the innovation process, versus
those which could be applied at an EU or national level for regulatory
decisions. Of those that could become applicable in regulatory context,
focus is put on the risk assessment frameworks that are more detailed
and cover a broad range of nanomaterials and exposure routes. All risk
assessment frameworks would benefit from being tested for reliability
in case studies. These issues were considered in Table 1, addressing the
aim, regulatory readiness, advantages, and disadvantages for the var-
ious risk assessment frameworks. The obtained insights, and how the
use of the frameworks can facilitate the need for increased efficiency in
information gathering for risk assessment of nanomaterials constitute a
different evaluation process, relative to those done in the recent past
(Grieger et al., 2012; Hristozov et al., 2016). In addition, the present
manuscript includes recent developments relative to the assessment of
the regulatory perspective on early frameworks in Hristozov et al.
(2012).
3. Overview of risk assessment frameworks
The selected risk assessment frameworks that are specific for na-
nomaterials are listed in Table 1. Although the frameworks are based on
the same risk assessment paradigm, consisting of hazard identification,
exposure assessment and risk characterisation, the frameworks are di-
verse in their aim, applicability domain, basic assumptions and align-
ment to one or more regulations. Since each framework is specific to a
purpose, it is not possible to take various components from them to
construct an adequate risk assessment framework to suit all routes of
exposure for mammalian and ecological receptors. Almost all the fra-
meworks lack the specific decision points and associated methods
needed for decision making that are required for actual application. For
the one framework that is specific enough, the decision points and as-
sociated methods cannot be fully evaluated based on current scientific
knowledge. For these reasons, it is not possible to clearly indicate the
best or most useful framework(s).
3.1. Scope, advantages and disadvantages
All but one of the frameworks lack the specific decision points and
associated methods needed for decision making that are required for
actual application. The DF4nanoGrouping framework is the only fully
elaborated risk assessment framework that transparently and in detail
includes clear decision criteria, triggers/cut-off values and tools to as-
sess inhalation risks (Arts et al., 2015, 2016). The framework also has
specific associated case studies (Arts et al., 2016; Landsiedel et al.,
2017). Just like other frameworks, however, an independent evaluation
of these criteria, triggers and methods has not yet been conducted. The
properties required by regulations such as REACH do not match with
the intrinsic material and system dependent properties needed by the
DF4nanoGrouping framework. Therefore, while the approach is de-
veloped, detailed and includes decision criteria, allowing it for to be
evaluated, the regulatory acceptability of this framework remains un-
clear.
The more elaborated of the risk assessment frameworks without
decision criteria, are the NANoREG nanospecific approach for risk as-
sessment described by Dekkers et al. (2016), and the NanoRiskCat by
Hansen et al. (2014). These frameworks are transparent and detailed,
and underpin their choices using scientific information (as far as pos-
sible) and build upon existing approaches for ‘conventional’ substances
(i.e. non-nanomaterials). These frameworks consider materials and
products, respectively. For screening of inhalation exposure in an oc-
cupational setting the general risk banding framework for inhalation of
low aspect ratio nanoparticles by Oosterwijk et al. (2016) can be useful,
whereas for environmental risks the general test strategy for assessing
the risks of nanomaterials in the environment by Hund-Rinke et al.
(2015) is more advanced. Further details on the different frameworks
can be found in Table 1. It should be noted that these frameworks re-
main qualitative.
The ECHA/JRC/RIVM approach on read-across between nanoforms
(ECHA/JRC/RIVM, 2016) constitutes scientifically-founded guidance
aimed at gathering information for a nanomaterial on one or more
hazard endpoints by using information from other materials, if possible.
The ECHA/JRC/RIVM read-across approach describes steps to consider
if existing information can be used in such a manner that sufficient
information is available to assess the risk/safety of an unassessed na-
noform, and how a read-across hypothesis can be substantiated (with
existing or additional information) (ECHA/JRC/RIVM, 2016). Read-
across between structurally similar substances is a generally applicable
approach in regulatory risk assessment of ‘conventional’ substances, as
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in REACH (Regulation EC/1907/2006). The ECHA/JRC/RIVM ap-
proach on read-across between nanoforms (of the same substance)
provides direction on how this concept can be applied to nanomaterials.
The stepwise approach, in which a hypothesis should be built to show
similarity (or be conservative) between the source and target material,
is the backbone of the read-across approach. The hypothesis can be
based on a kinetic argument in combination with a hazard argument.
The kinetic argument shows that a similar (or smaller) amount of a
target material reaches the (toxicological) target site in comparison to
the source material, while the hazard argument shows that the target
material is hazardous to a lesser or similar extent in comparison with
the source material.
Depending on the available information of the source material and
the substantiation of a read-across hypothesis, for each specific com-
bination of endpoint and nanoform, a data gap may be filled by read-
across. In that manner, the burden of testing that would otherwise be
required from a regulatory point of view to provide the necessary risk
assessment information for many nanoforms can be reduced. The
ECHA/JRC/RIVM approach on read-across between nanoforms of the
same substance outlines overarching principles on read-across to assess
if it is feasible to use information from one or more (source) nanoforms,
and how to substantiate such a read-across hypothesis (ECHA/JRC/
RIVM, 2016). This scientific reference paper has been used by ECHA to
develop guidance on grouping and read-across between nanoforms
(ECHA, 2017b). Hence, read-across provides a regulatory accepted
scientifically-based approach to fill an information gap on hazard, if
possible, and as such is an overarching principle that can be in-
corporated in other risk assessment frameworks.
As indicated, the risk assessment frameworks presented in Table 1
are very heterogeneous in their aim, scope, input and output informa-
tion. Hristozov et al. (2016) observed that the nanospecific frameworks
tend to become more quantitative and containing higher-tier models in
time. Some frameworks are directed towards risk assessment required
for regulatory approval before market admittance, such as the DF4na-
noGrouping framework (Arts et al., 2015, 2016) and the testing strategy
for nanomaterials in the environment by Hund-Rinke et al. (2015). The
LICARA nanoSCAN (Van Harmelen et al., 2016) that provides a quali-
tative assessment of potential benefits and risks of a new ‘nanoproduct’,
and the strategy described in NANoREG D6.04 (NANoREG, 2016) are
mainly intended to be used at an early stage in the innovation chain so
as to facilitate the development of sustainable safe(r) nanoproducts.
Such premarket frameworks aiming at safe(r) innovations can therefore
provide a win-win situation for policy makers and industry. The flow
chart by Dekkers et al. (2016) is applicable to nanomaterials that are
already on the market, and facilitates prioritisation of those nanoma-
terials that may lead to high exposure or high toxic potential. Those
elements related to exposure, toxicokinetics and hazard that are ex-
pected to be mostly influenced by nanospecific properties can also be
used in safe innovation processes (i.e. early in the innovation chain), as
well as in grouping and read-across approaches. Although there is no
evidence of a hazard that is only caused by nanomaterials and not by
other substances, nanomaterials can have different effects and/or po-
tencies than the same material in a non-nanoform. Also the NanoR-
iskCat tool by Hansen et al. (2014) can be used for prioritising nano-
materials, though the framework is more directed towards products
containing those nanomaterials. To assess the human hazard potential
they consider information on the aspect ratio, Classification & Labelling
information of the bulk, and existing information on genotoxicity/
mutagenicity, respiratory toxicity, cardiovascular toxicity, neurotoxi-
city, reproductive toxicity, carcinogenicity and organ accumulation
most relevant. These aspects are in part similar to the aspects con-
sidered most relevant for nanospecific human hazard by Dekkers et al.
(2016) and NANoREG D6.04 (2016): solubility/dissolution rate, stabi-
lity of coating/nanomaterial transformation, accumulation, genotoxi-
city and immunotoxicity/inflammation. The SUN Decision Support
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approaches to manage nanotechnology risks and sustainability, and
considers the links between these concepts.
The anticipated users of many frameworks are mostly manu-
facturers and developers, i.e. to give – in an economically efficient
manner – direction to the development of safe and sustainable products
or materials, and to gather the information needed for regulatory ap-
proval. The frameworks are also useful for risk assessors at govern-
mental bodies considering the need for additional information or risk
reduction measures, and to prioritise those applications and situations
that need to be considered first or most. All of the frameworks, except
the DF4nanoGrouping (Arts et al., 2015, 2016), are qualitative: they do
not provide clear triggers, protocols, and cut-offs for hazard and risk
decisions and thus require further development. Policy makers are
working on implementing or improving nanospecific adaptations to
current legislation or in some cases developing new pieces of legisla-
tion, for which the present frameworks can provide valuable input. For
mainstream application of risk assessment frameworks by industry,
regulatory acceptance is needed for their use and output.
Most frameworks focus on the hazard assessment of the pristine
nanomaterial. Some frameworks such as the DF4nanoGrouping (Arts
et al., 2015, 2016), the MARINA Risk Assessment framework (Bos et al.,
2015), the testing strategy for nanomaterials in the environment (Hund-
Rinke et al., 2015) and the ECHA/JRC/RIVM read-across approach
(ECHA/JRC/RIVM, 2016) explicitly consider changes in physicochem-
ical properties of the nanomaterials during their life cycle, but further
detailed results will be needed to apply this in practice. The idea of the
DF4nanoGrouping framework is to mark out the entire life cycle by
determination of ‘hotspots’ with likely occupational or consumer ex-
posure. The ECHA/JRC/RIVM report envisions a read-across type of
hypothesis between the pristine nanomaterial and the nanomaterial as
present in different life cycle stages. To address the issue of life cycle,
Potthoff et al. (2015) developed a series of decision trees and flow
charts to support the testing of nanomaterials, for example differ-
entiating between relevant/probable conditions and worst-case condi-
tions. In the case of the latter, stable dispersions of the pristine material
are used. In case of relevant/probable conditions, this should be re-
flected in the type of test material and the potential for agglomeration.
Nowack et al. (2016) developed an approach to obtain sufficient
quantities of released materials to study these materials.
Some frameworks build on previously-established frameworks. This
is for example the case for the DF4nanoGrouping framework, which
consists of a series of publications by Arts et al. (2014, 2015, 2016) and
Landsiedel et al. (2017), and builds upon previous work by Gebel et al.
(2014). The ECHA/JRC/RIVM report on read-across between nano-
forms (2016) relies on previous work, e.g. by Sellers et al. (2015) and
references above, as well as on considerations on grouping and read-
across approaches for risk assessment of nanomaterials as described by
Oomen et al. (2015). The flow chart by Dekkers et al. (2016) and the
screening strategy described in NANoREG D6.04 (2016) are both pro-
ducts that were coordinated by RIVM as part of the NANoREG project,
and in both documents the same risk potentials or aspects of exposure,
kinetics and hazard assessment that are considered most likely to be
influenced by the nanospecific properties have been put forward.
3.2. Physicochemical properties used in risk assessment frameworks
Identification and characterisation of nanomaterials is considered a
prerequisite first step in most risk assessment strategies. This informa-
tion allows identification of existing information of those particular
materials, and to target the information gathering process needed for
risk assessment. Differences between frameworks can be observed with
regard to the physicochemical properties that are considered.
Physicochemical properties used for the most elaborated risk assess-
ment frameworks as discussed in Section 3.1 are listed in Table 2 below.
Analytical methods for physicochemical characterisation are discussed
by Lowry et al., in this issue.
Some frameworks such as DF4nanoGrouping (Arts et al., 2015,
2016), Dekkers et al. (2016) and NANoREG D6.04 (2016) mention, list
and/or make reference to test methods that can be used to measure the
indicated key physicochemical properties or aspects considered key for
risk assessment of nanomaterials. However, further guidance on how to
interpret the data of such testing is lacking, except for the DF4nano-
Grouping framework.
As can be seen in Table 2, although differences in information needs
in the different risk assessment frameworks are visible, the chemical
composition, presence of impurities, shape, particle size and surface
properties are typically mentioned. Information on solubility/dissolu-
tion is also considered important.
4. Specific considerations in risk assessment
As already indicated, the current principle of risk assessment that
combines information on exposure and hazard endpoints applies to
nanomaterials. However, nanomaterials show particle-specific beha-
viour and, as a consequence, require some specific considerations.
These nanospecific issues should be considered in risk assessment fra-
meworks. Several important considerations are addressed below in
Sections 4.1 and 4.2.
4.1. Nanoforms
It has been shown that different nanoforms can display different
behaviour both in their fate/toxicokinetics and hazard, and thus in risk.
It is therefore logical to consider this in those dossiers for regulatory
acceptance that comprise more than one nanoform. A start is being
made by guidance in development by ECHA on the term ‘nanoform’
(ECHA, 2017a). As long as different nanoforms are not addressed, this
can be considered a regulatory gap which requires further research and
policy considerations.
4.2. Life cycle and exposure
It is known that physicochemical properties of nanomaterials re-
levant for their potential risk may change during their life cycle (OECD,
2012a; Gottardo et al., 2017), whereas normally the pristine material is
used for toxicity testing. Therefore, the issue of including life cycle
considerations in the risk assessment of nanomaterials has been raised
by many scientists and considered in general terms in risk assessment
frameworks (see Section 3.1) (Bos et al., 2015; Oomen et al., 2014;
Sellers et al., 2015; Arts et al., 2015; Hendren et al., 2015; Nowack
et al., 2016; Erdely et al., 2016; Dekkers et al., 2016). To enable toxicity
testing of released nanomaterials, standardised procedures to obtain
fragmented products from nanomaterials incorporated in products are
being developed (Kuhlbusch et al., in this issue). Hazard studies with
well-dispersed pristine materials would probably result in most cases in
an overestimation of the risk, as these well dispersed pristine materials
are expected to represent a worst-case situation (Potthoff et al., 2015).
In specific conditions, however, more hazardous nanomaterials may be
formed during the life cycle, for example due to disintegration of a
coating or photo-activation. Further investigation when these life cycle
changes may lead to more hazardous nanomaterials than their pristine
counterpart may be relevant. On the other hand, hazard testing of the
material as representative for the realistic situation rather than the
well-dispersed pristine material would result in more realistic risk as-
sessment. This would require additional work, i.e. to obtain the relevant
material for the (potentially many) relevant situation(s) for human
health and the environment, though from a scientific point of view this
would result in the scientifically most correct risk characterisation.
In order to consider changes of the nanomaterial during the life
cycle in the risk assessment, it must be possible to measure the nano-
materials and their physicochemical properties in complex matrices.
Quantitative measurement of concentrations of nanomaterials at
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realistic conditions is very complicated, expensive and time consuming.
This is especially the case if also physicochemical properties, such as
degree of agglomeration, size distribution, etc., are to be measured
under realistic conditions in complex matrices. Development of com-
putational models to estimate such exposures and changes in physico-
chemical properties during the life cycle is therefore highly re-
commended.
4.3. Delivered dose
Attention should be paid to the tendency of nanomaterials to ag-
glomerate, as that can have serious impact on factors like dilution, in-
ternalised dose, and application of assessment factors (Lützhøft et al.,
2016; van Kesteren et al., 2014; Holden et al., 2016). High dose studies
can give results not representative for lower concentrations due to ag-
glomeration and subsequent lower biological uptake, biological barrier
penetration, or sedimentation affecting the internal exposure (van
Kesteren et al., 2014; Holden et al., 2016), or in cases where effect
mechanisms do not scale with concentrations (Holden et al., 2016). As a
consequence, the degree of agglomeration at the concentration that is
identified as a No Observed Effect Concentration (NOEC) may be higher
than the safe concentration that is derived from the NOEC after appli-
cation of assessment factors (Lützhøft et al., 2016). Also flotation on the
(water) surface may affect the degree of uptake and thus the inter-
nalised dose (Hund-Rinke et al., 2015). Hence, the internalised and
nominal dose may thus not be related (Holden et al., 2016; Lützhøft
et al., 2016; OECD, 2012a). In other words, if the results of a high dose
study are used to set a (no) effect concentration, which is subsequently
used to estimate a safe concentration by applying assessment factors,
the risk may be “underpredicted” (van Kesteren et al., 2014; Lützhøft
et al., 2016), i.e. such an estimated safe concentration may not be safe.
It is therefore recommended to determine the form (physicochemical
properties) and concentrations of nanomaterials in the exposure
medium during and after testing (Holden et al., 2016), and to determine
representative internal concentrations (such as in liver and spleen or
environmental test organisms) in animal toxicity studies to obtain in-
sight into the amount of nanomaterial actually taken up in time (and
thus in the internalised dose at the target site). Examples of risk as-
sessment based on internal concentration are provided in van Kesteren
et al. (2014) and Heringa et al. (2016).
Information on internalised dose is thus considered highly relevant,
though still technically challenging. For the time being, making such
information mandatory may thus be difficult, but standard assessment
in research projects (including EU projects) can be considered. For in
vitro, a recent paper by DeLoid et al. (2017) proposes a model that can
estimate the nanomaterial dose that is delivered to cells over the course
of an in vitro exposure study based on limited input data specific to the
in vitro test situation. It should be considered that determination of the
internalised dose in in vivo studies would in many cases require addi-
tional animals. Nevertheless, such information is also useful to correlate
in vitro and in vivo data in order to find ways forward for alternative
testing (Oberdörster et al., in this issue, and Rothen-Rutishauser and
Drasler, in this issue), which may save animals in the long run.
4.4. Bioaccumulation
It is considered that bioaccumulation is a process delivering addi-
tional information for risk assessment of nanomaterials on ecotoxicity
(Hund-Rinke et al., 2015; Bos et al., 2015) and human health (Bos et al.,
2015; Dekkers et al., 2016; NANoREG D6.04, 2016; Hansen et al., 2014;
Arts et al., 2015, 2016) that is particularly important for nanomaterials
as their elimination from tissues can be very slow (i.e. years). It should
be noted that bioaccumulation is also relevant for hydrophobic non-
nanomaterials, where the octanol-water partition coefficient (Kow)
provides in a suitable functional assay. However, the tissues where
accumulation of such hydrophobic non-nanosubstances occur and basic
mechanisms of uptake and elimination differ from those of nanoma-
terials. In fact, the behaviour of nanomaterials cannot be described by
chemical equilibrium. As the octanol-water partitioning coefficient as-
sumes an equilibrium between the dissolved concentrations in the oc-
tanol and water phases, it is not a predictor for bioaccumulation or
environmental fate of nanomaterials (see Baun and Rose, in this issue,
and Nowack et al., in this issue).
For environmental risk assessment of nanomaterials, a pragmatic
screening procedure may be to determine the nanomaterial con-
centration in suitable test organisms (Hund-Rinke et al., 2015). For
human health risk assessment of nanomaterials, information on dis-
solution rate in physiologically relevant media such as lysosomal fluid
may give insight in the potential for accumulation. A more compre-
hensive view can be obtained by measuring internal tissue concentra-
tions (i.e. internalised dose) in toxicity studies at a few key time points,
and/or including measuring internal tissue concentrations before and
after a clearance period. Such data can be used to better address the
uptake (see delivered dose (Section 4.3)) and elimination and thus the
potential for accumulation. Linking toxicokinetic data, including in-
formation on accumulation and elimination, to physicochemical prop-
erties of the nanomaterial and to their dissolution rate in physiologi-
cally relevant media may make this issue easier to handle in the future.
4.5. Assessment factors
The use of assessment factors for e.g. interspecies and intraspecies
differences is common practice in risk assessment of chemicals, al-
though also for chemicals a solid scientific rationale for the magnitude
of the factors is mostly lacking. It remains unclear if these standard
assessment factors for chemicals are also applicable for nanomaterials.
The OECD (2012b, 2015) indicates that there are insufficient data to
verify if the present standard assessment factors (AFs) of 10 for both
interspecies and intraspecies differences are applicable to nanomater-
ials. Indeed, insufficient studies are available that can be directly
compared to each other to allow assessment of the variation between
studies. Toxicity information for non-nanosubstances has accumulated
over decades and has a history-of-use, whereas for nanomaterials, ac-
quisition of data, and especially of good-quality data, is increasingly
emerging in the past few years. Furthermore, the variation in physi-
cochemical properties of a nanomaterial of the same elemental com-
position hampers direct comparison between studies: is a different re-
sponse the result of the intra- or interspecies variability, or due to
differences in the nanomaterial itself? To the best of our knowledge,
there are at present no datasets available that allow an adequate as-
sessment. Hence, for the time being it cannot be assessed whether na-
nomaterial-specific assessment factors are needed, and if so, what factor
that would be.
However, for the application of AFs for nanomaterials, pragmatic
choices could be made that are based on existing data, inherent un-
certainties of this data and extent of extrapolation, and consequent
incorporation of sufficient margins of safety (Dourson and Stara, 1983).
As there is no clear evidence that the current AFs for non-nanomaterials
are inappropriate, it could be an option to use the present standard AFs
until science allows for a better assessment. Alternatively, a more
conservative approach could be followed, in which an extra AF for
nanomaterials is introduced, in which case a discussion and decision
making on limited scientific evidence is needed on what specific factor
is appropriate.
4.6. Route-to-route extrapolation
In human health risk assessment, route-to-route extrapolation of
information occurs on a regular basis. However, there are few data to
support route-to-route extrapolation for nanomaterials (Gottardo et al.,
2017). The media for exposure via lung (air), gastrointestinal tract
(gastrointestinal fluids), skin, and intravenous application typically
A.G. Oomen et al. NanoImpact 9 (2018) 1–13
8
differ greatly. These media as well as the conditions at the site of
contact may affect the properties of a nanomaterial considerably, and
thus their behaviour and risk. Further insight into the possibilities for
extrapolation of hazard information that is gained from studies with
different exposure routes is therefore recommended.
4.7. Functional assays in risk assessment frameworks
Because the understanding of the relationship between physico-
chemical properties of nanomaterials and their toxicokinetic/fate be-
haviour and hazard potential still is limited, several functional assays
have been suggested in literature as additional tests and triggers for use
in nanomaterial risk assessment. Such functional assays give a read-out
depending on the combination of a nanomaterial and specific – external
– conditions. Functional assays properties include the surface affinity
(also referred to as ‘stickiness’) as suggested by Hendren et al. (2015)
and the dissolution rate under relevant environmental or physiological
conditions for characterising nanomaterial behaviour in a variety of
important systems. Hendren et al. (2015) proposes functional assays to
measure nanomaterial behaviour in environmentally relevant systems,
as current approaches to predict risk directly from intrinsic nanoma-
terial properties are problematic. The outcome of such a functional
assay could be relevant for assessing the most relevant environmental
fate routes and highlight needs for associated risk assessment endpoints
and could thus be integrated to improve the efficiency of risk assess-
ment frameworks for nanomaterials. Surface affinity (α) describes the
probability of particle attachment when particles collide with another
particle or a stationary “collector” surface. It determines the mobility of
nanomaterials (and other small particles) in environmental matrices
such as porous media, and relates to their propensity to (hetero)ag-
gregate and, in some cases, the reactivity of nanoparticle aggregates.
Surface affinity measures of nanomaterials may therefore have im-
plications for both the fate of a nanomaterial in the environment, and
its potential toxicity/ecotoxicity. It is suggested that functional assays
can support near-term regulatory guidance and sustainable product
development. Yet, as for other tools and methods that aim to become
regulatory accepted, this would require consensus on the application of
the functional assay, including how to standardise the assay, and how
to interpret the assay results in a regulatory context. This would imply a
major change in the current practice of regulatory frameworks and
scientific and regulatory efforts to come to decisions on the use and
application of such functional assays. If clear relationships between
output of a functional assay and a risk related parameter can be made,
functional assays such as for surface affinity can indeed provide added
value in risk assessment. For example, in regulatory environmental risk
assessment of non-nanosubstances, the octanol-water partitioning
coefficient is a convenient functional assay for likelihood of soil ad-
sorption and bioaccumulation of that substance.
Other functional assays that are considered promising for nanoma-
terials are dissolution rate in relevant media, and surface reactivity
(Lowry et al., in this issue). Dissolution rate describes the speed at
which the nanoparticles form a solution in a given solvent, and may be
critical for predicting both the persistence, toxicokinetics/fate of and
hazard posed by nanomaterials. Dissolution rate in physiologically re-
levant conditions is also proposed and applied in the DF4nanoGrouping
risk framework and NANoREG nanospecific approach for risk assess-
ment by Dekkers et al. (2016). Fast dissolution in physiologically or
environmentally relevant media in view of physiologically and en-
vironmentally relevant time frames is considered to provide options for
read-across to the solute at an early stage of the risk assessment process
as proposed by Oomen et al. (2015). When the nanomaterial dissolves
only partially within an environmentally or physiologically relevant
time-frame, things become more complicated with behaviours similar
to mixture toxicity. In a review of available data and knowledge gaps
for nano‑silver by Wijnhoven et al. (2009), it was suggested that the
toxic effects of nano‑silver can be due to a combination of the specific
properties of silver nanoparticles and the generation of ions from them.
Determining whether future research would need to focus on na-
no‑silver particles only, on silver ions only, or both, would be key.
Additional efforts would be needed for a thorough risk assessment,
especially in the case that both the ion and the particulate form need to
be considered, or similarly, in case a coating is degraded and both the
core nanomaterial and the nanomaterial with a coating need to be
considered. Dissolution and agglomeration are in the OECD validation
process as TGs, containing initial considerations on the interpretation of
the assay results for regulation. Yet, before application in regulatory
frameworks can be considered, currently available functional assays
appear to require better understanding and validation.
Dekkers et al. (2016) and NANoREG D6.04 (2016) consider dis-
solution as one of the six aspects that are most relevant for nanoma-
terial exposure, kinetics and/or hazard. Hund-Rinke et al. (2015) sug-
gests a screening on the durability of a nanomaterial, referring to the
extent that nanomaterials remain intact. Durability by Hund-Rinke
et al. (2016) is exemplified by rapid dissolution, indicating that dis-
solution and durability are related. Taken together, dissolution rate
under relevant conditions can provide unifying information that is re-
levant for regulation. However, similar to surface affinity, further in-
sights are needed on the relevant media and conditions, as well as in-
formation on the reproducibility and reliability, and the interpretation
of the outcome.
Surface reactivity is considered a potential unifying factor for a
mode-of-action of nanomaterials (Delaval et al., 2017; Gandon et al.,
2017). Surface reactivity can e.g. induce oxidative stress, which may
result in inflammation related effects. Surface reactivity is considered a
key descriptor for hazard in grouping and read-across approaches
(ECHA/JRC/RIVM, 2016; Oomen et al., 2015 – see Lowry et al., in this
issue and Oberdörster et al., in this issue on generation of reaction
oxygen species ROS). Similar to other functional assays, assays on
surface reactivity would require better understanding and validation
before application in regulatory frameworks can be considered.
The relevance and need for developing internationally accepted
guidance and test guidelines especially for surface affinity, dissolution
in relevant media, and surface reactivity is clear. These assays should be
suitably placed in risk assessment frameworks to make use of their
potential to address nanospecific behaviour and hazard. It is also es-
sential to develop guidance on the interpretation of the outcome of such
tests.
4.8. Case studies
Some publications are available on the risk assessment of specific
nanomaterials incorporated in products (Voelker et al., 2015; Dekkers
et al., 2013; van Kesteren et al., 2014; Heringa et al., 2016; Wohlleben
et al., 2011). This case-by-case approach allows for detailed adjust-
ments relevant to the specific case, and provides food-for-thought by
pointing towards important elements to be considered in the risk as-
sessment of nanomaterials.
5. Elements for improving the feasibility to assess the risk of
nanomaterials
The present section addresses issues to increase the feasibility to
perform risk assessment of nanomaterials in practice.
5.1. Standardised testing
As can be observed in the other manuscripts of this Special Issue, the
knowledge to correctly apply and/or modify tools, tests and methods to
obtain information relevant for risk assessment of nanomaterials is in-
creasing. Interferences, artefacts and unstable or unknown exposure
conditions are better understood and dealt with, or alternatives are (to
be) sought. To bring this knowledge into practice, protocols, guidance
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and suitable controls and reference materials are being developed, and
standardisation activities are ongoing or can be launched.
Internationally acknowledged guidance documents to standardise
testing of nanomaterials are therefore considered highly necessary for
risk assessment frameworks. For example, the OECD Guidance on
Sample Preparation and Dosimetry (OECD, 2012b) is helpful to con-
sider when conducting both health and ecotoxicity testing. The OECD
Guidance document on Aquatic and Sediment Toxicological Testing of
Nanomaterials (OECD, 2017), the OECD Fate Decision Trees (OECD,
2014) and the OECD Guidance document on Fish Dietary Accumulation
Studies for Engineered Nanomaterials (OECD, 2015) – some still to be
finalised – are useful for prioritising testing needs. Worldwide harmo-
nisation of such testing approaches via the OECD is considered valuable
in general due to their consensus-driven review and acceptance by
regulatory authorities from many countries.
Standardisation of test protocols and assurance of high quality data
(including sufficient quality controls) is of the utmost relevance for
acquiring reliable and reproducible data that can be used in risk as-
sessment of nanomaterials in general.
5.2. Development of in vitro-in vivo comparison
Scientific understanding to enable linking in vitro and in vivo tests is
required to rely more on in vitro results in risk assessment. The risk
assessment frameworks reviewed here do not suggest any unifying dose
metric for linking in vitro and in vivo tests. Information on the dose
reaching the target site (the internalised dose) both in in vitro and in vivo
situations would probably help when comparing the results, as the
fraction of nanomaterial reaching the target site is highly influenced by
the experimental setting, both in in vitro and in vivo testing. Based on
such comparisons, further considerations may then help to link in vitro
and in vivo tests and to assess the applicability of in vitro data for risk
assessment purposes of nanomaterials.
Also, information on the internalised dose, i.e. the amount of na-
nomaterials reaching the target site (i.e. environmental organism, cells
in in vitro test systems, organs in test animals, etc.) is highly relevant for
correct interpretation of the experimental results.
In vitro studies can be very useful for hazard and biokinetic assess-
ment, though direct correlation of the in vitro studies for environmental
or human health risk is still not yet possible. As a start, Landsiedel et al.
(2014) compared data form in vitro assays to in vivo instillation and
inhalation data. In the short term, in vitro studies can be expected to
become useful for mechanistic information, i.e. to assess which mode of
action (MOA) is expected to be most relevant for a specific nanoma-
terial. In addition, ranking hazard potency and biokinetic behaviour
(i.e. cellular uptake, fate, and translocation across barriers) by in vitro
studies is likely to provide relevant information for regulatory risk as-
sessment. This is especially the case when such in vitro information can
be compared to information from reference nanomaterials. Finally, test
batteries which comprise different organ systems such as described by
Farcal et al. (2015) may be used as a general screening tool for nano-
materials, though further comparison of the predictability of such in
vitro test batteries to the in vivo situations would be needed. Further
discussion on in vitro and in vivo tools and approaches for nanomaterials
are provided in Oberdörster et al., in this issue, and Rothen-Rutishauser
and Drasler, in this issue. Continuation of these comparison and stan-
dardisation activities is thus highly recommended.
5.3. Benchmark materials
Nanomaterials with good-quality physicochemical characterisation
and exposure and/or (chronic) hazard studies are needed as standard
and to assess the reliability and reproducibility of other tests.
5.4. In silico approaches
In silico approaches may help to target testing of nanomaterials. The
present in silico approaches mainly relate to straightforward in vitro
data, as only on such endpoints sufficient data are available, and have
therefore limited accuracy for in vivo situations. The limited amount of
available data also limits the applicability domain of available in silico
approaches. Therefore, the current added value of in silico approaches is
limited, although it is expected to increase in the future. Further as-
sessment on in silico approaches is provided in Burello et al., in this
issue.
6. Efficiency and uncertainty in risk assessment frameworks
A range of different risk assessment frameworks aiming to deal with
the complexity of risk assessment of nanomaterials have been described
in the literature (see Table 1). Most of the risk assessment frameworks
lack details regarding decision criteria and tools to allow actual appli-
cation. All frameworks struggle with how to deal efficiently with the
multitude of potentially different nanomaterials due to (slightly)
varying physicochemical properties. When potential consequences for
human health and for the environment due to this multitude of varying
properties are more thoroughly addressed (e.g. by gathering/generating
more data), the efficiency of the framework decreases. It is anticipated
that a major hurdle in constructing and implementing efficient risk
assessment frameworks in product and substance/material regulations,
will be the choices/decisions to be made that result in uncertainty in the
number of false negatives. In the case of a false negative, a nanoma-
terial is allowed on the market where it poses an unacceptable risk. For
example, if a cut-off value for dissolution rate is proposed, this value is
either highly conservative (only the immediately dissolving materials
can be waived to their solutes, meaning that many nanomaterials still
remain to be assessed), or uncertainty arises from the consequences of a
more pragmatic choice. Science is at present not sufficiently advanced
to give a quantitative estimation of the chance of false negatives. This
uncertainty is biggest for potential effects after chronic exposure. As
this kind of information (mostly from long-term animal studies) is
ethically debatable and expensive, knowledge can be expected to pro-
gress slowly here (Gottardo et al., 2017). Yet, it has been shown that
nanoparticles can accumulate in tissues/organisms over time, in-
dicating that with increasing tissue/organism loading in time also the
likelihood of adverse effects increases. This means that it is important to
investigate whether effects occur after long-term exposure. Also po-
tential immunotoxicity and neurotoxicity have been linked to nano-
materials, though are difficult to measure and data still mainly comes
from long-term in vivo tests. Taken together, these considerations show
a major challenge for risk assessment of nanomaterials: the urgent need
for efficient risk assessment with a focus on potential chronic effects,
limited availability of existing, good-quality information, and high cost
and time efforts needed to increase this information. From a policy
point of view, the efficiency of risk assessment of large numbers of
nanomaterials can be increased with practical, only partially scientifi-
cally underpinned choices. Alternatively, read-across, prioritisation and
comparative techniques can bring some efficiency, but would clearly
not solve the entire issue, especially not for the near future, considering
the required substantiation of grouping and read-across and the limited
available information. These options are further developed under future
perspectives in this chapter.
A way to shift the issue of uncertainty on false negatives in risk
assessment frameworks is prioritising those nanomaterial-applications
with the highest potential risk, as proposed by Dekkers et al. (2016).
Also frameworks that aim at considerations on human health or en-
vironmental risk early on in the innovation chain can be based on
comparisons or risk indications rather than quantitative risk assess-
ment. Although highly useful also in a regulatory sense, this does not
allow for efficiently fulfilling the regulatory requirements for
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legislation, e.g. REACH. To enable decisions to be made about efficient
risk assessment frameworks in the near future, or application of (parts
of) risk assessment frameworks in existing regulations, international
agreement is required on practical cut-off and trigger values, while
realising that these can only be scientifically founded to a limited ex-
tent. This would require dialogue between stakeholders, in which the
uncertainty associated with the state-of-the-art science is addressed,
made transparent and dealt with. In order to make such a dialogue a
success, all stakeholders should be constructive and address and move
beyond underlying issues such as the lack of information on nanoma-
terials in the current regulatory frameworks and the fear of extensive
additional testing. Communication to the public at large that “zero risk”
does not exist is essential to provide fair expectations on risk assess-
ment.
If no action is taken, either innovation can be substantially ham-
pered due to the need for a huge number of case-by-case risk assess-
ments, or large numbers of nanomaterials reach the market without or
with only limited knowledge on their potential risk. Hence, interna-
tional agreement to come to efficient risk assessment of nanomaterials
is recommended. This should take science into account as far as pos-
sible, while acknowledging that scientific insights are still premature
for complete substantiation. Other risk assessment approaches that
focus on prioritisation, substitution and on safety considerations during
the innovation chain are relevant, and it is recommended that efforts in
these fields continue. Further future perspectives are provided below.
It should be noted that also false positives are unwanted. False
positives in the present setting are nanomaterials/products that are not
allowed to the market because of assumed unacceptable risk, where in
fact the risk is acceptable. This would hamper innovation.
7. Future perspectives to increase efficiency in risk assessment of
nanomaterials
A key issue in acceptance and application of risk assessment stra-
tegies in a regulatory setting is that adequate information for safety
assessment of nanomaterials is obtained.
Outside the regulatory legal framework arena, addressing human or
environmental risk early on in the innovation chain is relevant to re-
duce the number of nanomaterials with a safety issue and avoid in-
vestment in further product development which will eventually not
yield a marketable product due to high risk for humans and/or the
environment. This can be a win-win situation for innovators and reg-
ulators, as both benefit from reduced uncertainty on risk.
With regard to nanomaterials that reach regulatory evaluation, two
broad options can be distinguished to increasing the efficiency in
gathering information for risk assessment.
7.1. Option 1
Continue in line with current regulation (e.g. REACH). For nano-
materials some increase in efficiency is possible by grouping and read-
across approaches according to the outline described in the scientific
reference paper by ECHA/JRC/RIVM (2016). This document is cur-
rently the most aligned with REACH. Based on this document further
guidance has been developed (ECHA, 2017b).
Parallel to this development, a practical approach would be possible
for existing nanomaterials that are already on the market. A multi-
dimensional map of all forms within one substance differentiating in
key physicochemical properties can be made. The nanomaterials that
represent the most extreme key physicochemical properties, i.e. the
lowest and highest value of a range of e.g. size, or the worst case forms if
identifiable with reliable scientific substantiation, can be used to obtain
hazard information that may be used for a group of nanoforms.
7.2. Option 2
Stratify the information needs according to the anticipated potential
for hazard/risk in order to focus more on nanomaterials with the
greatest potential for hazard/risk. To further increase the efficiency in
addressing nanomaterials in risk assessment, pragmatic, partially sci-
entifically underpinned choices for decision criteria (cut-off values,
trigger values, in vitro tests, functional assays and other tools like high
throughput systems (HTS) and - in future - in silico approaches, etc.)
would be applied to risk assessments of nanomaterials. Such choices can
only be partially scientifically based, as science is not sufficiently ad-
vanced and is not expected to provide well-founded science-based
mechanisms to efficiently deal with risks in the near future, especially
where chronic exposure is relevant. Such an approach would require
cooperation of policy makers, scientists and industry and agreement on
an international level. Attention should be paid to the operational
process in such cooperation, for example by starting with a dialogue. If
such an approach would be pursued, aspects most likely to be influ-
enced by nanospecific properties can be used as a starting point. Several
studies indicate that exposure, solubility/dissolution rate, stability of
coating, accumulation, genotoxicity, inflammation, ecotoxicity and
environmental fate are important nanospecific properties (Dekkers
et al., 2016; NANoREG D6.04, 2016, and to some extent also Hansen
et al., 2014; Arts et al., 2015, 2016; Hund-Rinke et al., 2015, and
Oosterwijk et al., 2016).
Also, the decision criteria and tools as proposed by the DF4Nano
Framework (Arts et al., 2015, 2016) can be independently investigated
on their methodology and the likelihood of giving false negative out-
comes. The outcome of the case studies as performed by the authors of
the DF4NanoFramework should be included in this process (Arts et al.,
2016).
Another tool to address uncertainties in such analyses is to apply
additional risk management controls such as workplace engineering
controls, protective equipment and restricted environmental releases
until additional data are provided.
For nanomaterials already on the market, aspects of option 2 can be
applied as a start. The thus obtained insights can be used in the first
place to regulate the most hazardous nanoforms according to the cur-
rent understanding. Subsequently, a more generic understanding on the
behaviour of nanomaterials can grow continuously. This will add to a
knowledge base to allow for the improved applicability of grouping and
read-across of nanomaterials in regulatory frameworks, and to the
feasibility of pragmatic, partially scientifically underpinned choices for
decision criteria, tests and tools.
It should be noted that the present assessment is based on scientific
knowledge that is gained from ‘the first generation’ of nanomaterials,
which comprise relatively simple inorganic and carbon-based nano-
materials. It is recommended to actively monitor scientific develop-
ments of future innovations and assess potential consequences for
human and environmental risk, and determine whether the legal fra-
meworks are sufficiently equipped to deal with these innovations.
8. Conclusions
In conclusion, ongoing efforts in improving the current risk assess-
ment frameworks to include nanomaterials need to be continued. With
nanomaterials, some issues such as exposure (stable dispersions, re-
levance of high dose studies, assessment of internalised dose), bioac-
cumulation, in vitro-in vivo comparison and long-term effects deserve
special attention. Furthermore, activities to standardise and develop
protocols and guidance documents, including for several functional
assays, as well as suitable controls and reference materials should
continue.
Risk assessment frameworks that aim to prioritise or substitute na-
nomaterials of highest concern, as well as frameworks that aim to in-
troduce safety considerations into the innovation chain, are gradually
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becoming more concrete. Further evaluation of such frameworks via
case studies and success stories are needed to improve these frame-
works and pave the way for mainstream application, also for regulatory
needs. To include nanomaterials (or nanoforms) in risk assessment
regulations in an efficient manner, i.e. beyond the case-by-case ap-
proach, consensus is needed with regard to e.g. cut-off values and
benchmark materials as well as suitability of simple tools and tests for
which the present knowledge base is insufficient. Grouping and read-
across approaches can bring some efficiency to the case-by-case as-
sessment. Considering the required scientific substantiation of grouping
and read-across and current limitations in available data and knowl-
edge on relationships between physicochemical properties and nano-
material behaviour, however, these approaches are also not expected to
bring the required efficiency in risk assessment of nanomaterials for the
near future. Nevertheless, developments in grouping and read-across
may accelerate the assessment of existing relevant information and
gaining of new information. In addition to pragmatic decisions to deal
with nanomaterials in the current situation, further research is needed
to increase the scientific knowledge on the risks of nanomaterials. The
focus should be on systematic studies that facilitate the understanding
of the behaviour of nanomaterials, especially related to long-term ef-
fects. In such studies information on internal concentrations (also re-
ferred to as internalised dose) would have added value. Such in-
formation would be useful to substantiate or adapt cut-off values and
other decisions in risk assessment frameworks, and facilitate in
grouping and read-across approaches.
Finally, attention should be paid to organising the operational
process to get to efficient risk assessment approaches for nanomaterials,
including cooperation between parties to come to harmonised ap-
proaches and investing in curation processes to acquire a reliable set of
data on nanomaterials.
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